SEARCH

SEARCH BY CITATION

References

  • 1
    Otten RA, Smith DK, Adams DR et al. Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2). J Virol 2000; 74: 97719775.
  • 2
    Tsai CC, Emau P, Follis KE et al. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol 1998; 72: 42654273.
  • 3
    Connor EM, Sperling RS, Gelber R et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 study group. N Engl J Med 1994; 331: 11731180.
  • 4
    Sperling RS, Shapiro DE, Coombs RW et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med 1996; 335: 16211629.
  • 5
    Centers for Disease Control. Case-control study of HIV seroconversion in health care workers after percutaneous exposure to HIV-infected blood: France, United Kingdom and United States, January 1988–August 1994. Morb Mortal Wkly Rep 1995; 44: 929933.
  • 6
    Cardo DM, Culver DH, Ciesielski CA et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for disease control and prevention needlestick surveillance group. N Engl J Med 1997; 337: 14851490.
  • 7
    Centers for Disease Control. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States. Morb Mortal Wkly Rep 2005; 54 (no. RR-2): 120.
  • 8
    Katz MH, Gerberding JL. Postexposure treatment of people exposed to the human immunodeficiency virus through sexual contact or injection drug use. N Engl J Med 1997; 336: 10971100.
  • 9
    Bernasconi E, Jost J, Ledergerber B et al. Antiretroviral prophylaxis for community exposure to the human immunodeficiency virus in Switzerland, 1997–2000. Swiss Med Wkly 2001; 131: 433437.
  • 10
    Rey D, Bendiane MK, Moatti JP et al. for the European Study Group on HIV Testing Policies and Practices in Europe. Post-exposure prophylaxis after occupational and non-occupational exposures to HIV: an overview of the policies implemented in 27 European countries. AIDS Care 2000; 12: 695701.
  • 11
    Gostin LO, Lazzarini Z, Alexander D et al. HIV testing, counseling, and prophylaxis after sexual assault. JAMA 1994; 271: 14361444.
  • 12
    Wiebe ER, Comay SE, McGregor M, Ducceschi S. Offering HIV prophylaxis to people who have been sexually assaulted: 16 months' experience in a sexual assault service. CMAJ 2000; 162: 641645.
  • 13
    Teixeira Garcia M, Moralez Figueiredo M, Moretti ML et al. Postexposure prophylaxis after sexual assaults: a prospective cohort study. Sex Trans Dis 2005; 32: 214219.
  • 14
    Swiss Federal Office of Public Health. Preliminary recommendations for HIV post-exposure prophylaxis outside the medical setting. Bull OFSP 1997; 50: 46.
  • 15
    Swiss Federal Office of Public Health. Recommendations for HIV post-exposure prophylaxis outside the medical setting – update 2006. Bull OFSP 2006; 36: 712715.
  • 16
    Kahn JO, Martin JN, Roland ME et al. Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP study. J Infect Dis 2001; 183: 707714.
  • 17
    Poyten IM, Smith DE, Cooper DA et al. The public health impact of widespread availability of nonoccupational postexposure prophylaxis against HIV. HIV Med 2007; 8: 374381.
  • 18
    Martin JN, Roland ME, Neilands TB et al. Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior. AIDS 2004; 18: 787792.
  • 19
    Schechter M, Do Lago RF, Mendelsohn AB et al. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. J Acquir Immune Defic Syndr 2004; 35: 519525.
  • 20
    Roland ME, Martin JN, Grant RM et al. Postexposure prophylaxis for human immunodeficiency virus infection after sexual or injection drug use exposure: identification and characterization of the source of exposure. J Infect Dis 2001; 184: 16081612.
  • 21
    Myles JE, Hirozawa A, Katz MH et al. Postexposure prophylaxis for HIV after sexual assault. JAMA 2000; 284: 15161518.
  • 22
    Siika AM, Nyandiko WM, Mwangi A et al. The structure and outcomes of a HIV postexposure prophylaxis program in a high HIV prevalence setup in western Kenya. J Acquir Immune Defic Syndr 2009; 51: 4753.
  • 23
    Pinkerton SD, Martin JN, Roland ME et al. Cost-effectiveness of postexposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus. Arch Intern Med 2004; 164: 4654.
  • 24
    Roland ME, Neilands TB, Krone MR et al. Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clin Infect Dis 2005; 41: 15071513.
  • 25
    Almeda J, Casabona BJ, Simon B et al. Proposed recommendations for the management of HIV post-exposure prophylaxis after sexual, injecting drug or other exposures in Europe. Available at http://www.eurosurveillance.org/em/v09n06/0906-223.asp (accessed 2 December 2008).
  • 26
    Greub G, Gallant S, Zurn P et al. Spare non-occupational HIV post-exposure testing by active contacting and testing of the source person. AIDS 2002; 16: 11711176.
  • 27
    Swiss Federal Office of Public Health. Characteristics of HIV epidemics in Switzerland in 2008. Available at http://www.bag.admin.ch (accessed 21 April 2009).
  • 28
    Giulieri S, Schiffer V, Yerly S et al. The trap: professional exposure to human immunodeficiency virus antibody-negative blood with high viral load. Arch Intern Med 2007; 167: 25242526.